Cidara Therapeutics, Inc..
CDTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. The company's primary focus is on developing therapies to treat fungal and viral infections. Their pipeline includes drug candidates targeting serious systemic ...Show More
Better Health for All
50
Cidara Therapeutics' core business is entirely focused on developing novel anti-infectives and therapies for serious diseases, with 100% of its product portfolio, including CD388 for influenza and CBO421 for solid tumors, designed to provide substantial health benefits and save lives.
1
The company has no revenue from products with negative health outcomes. Its lead candidate, CD388, is a non-vaccine influenza preventative that demonstrated up to 76% efficacy in Phase 2b trials and is being evaluated in Phase 3 trials targeting high-risk and vulnerable populations, with a target enrollment of 6,000 participants.
2
CD388 has received Fast Track and Breakthrough Therapy Designations from the FDA.
3
The company has also secured an award from BARDA valued up to $339 million to ensure U.S. supply of CD388 in the event of an influenza pandemic.
4
Cidara invests significantly in health innovation, with R&D expenses of $71.9 million in 2024, representing over 25% of its total operating expenses.
5
The company's clinical trials for CD388 and CBO421 are ongoing, with a Phase 3 study for CD388 enrolling participants in 150 sites across the U.S. and UK.
6
Fair Money & Economic Opportunity
0
Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial services or products to consumers.
2
Therefore, all KPIs related to Fair Money & Economic Opportunity are not applicable to the company's operations.
Fair Pay & Worker Respect
0
No specific, quantifiable data points were found across the provided articles for any of the Fair Pay & Worker Respect KPIs, such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage. While Cidara Therapeutics was recognized as a 'Top Workplace' in San Diego for multiple years (2018, 2020, 2021) and reported high employee survey participation rates (100% in 2018, 97% in 2020, 95% in 2021),
1
the articles explicitly state that no specific quantitative engagement scores were provided.
2
Therefore, no KPIs can be scored based on the available evidence.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles regarding Cidara Therapeutics, Inc.'s performance on fair trade and ethical sourcing KPIs.
1
The articles did not contain information on fair-trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
2
Honest & Fair Business
0
No specific, concrete evidence was found across the provided articles to assess Cidara Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs. While ISS Governance QualityScore pillar scores for Audit and Board were mentioned, these are proprietary scores and not direct quantitative measures (e.g., percentages of audit coverage or conflict-free board members) that align with the rubric's specific thresholds for scoring.
1
Kind to Animals
-40
The company uses cell-based assays to assess drug activity, but also conducts animal studies in mice and cynomolgus macaques for efficacy and pharmacokinetic experiments.
1
Animal studies were performed in facilities accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and approved by Institutional Animal Care and Use Committees (IACUC).
2
The animal testing policy adheres to guidelines established in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.
3
For specific studies, 5 mice per group were used for efficacy, 3 female mice for PK experiments, and 3 female cynomolgus macaques for PK experiments.
4
No War, No Weapons
0
No evidence available to assess Cidara Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points were found in the provided articles for any of the 'Planet-Friendly Business' KPIs.
1
The articles primarily discuss company operations, financial updates, and an upcoming acquisition, without detailing environmental performance metrics or initiatives.
2
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided article to assess Cidara Therapeutics, Inc. against the 'Respect for Cultures & Communities' ethical value.
1
The article explicitly states that no relevant information is available.
2
Safe & Smart Tech
0
No evidence available to assess Cidara Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific data related to Zero Waste & Sustainable Products for Cidara Therapeutics, Inc. (CDTX.US) was found in the provided articles. explicitly states, "No sustainability data is available for CDTX."
1
Other articles focus on financial news, company pipeline, or general industry trends without providing company-specific metrics for waste management, product design, or packaging sustainability.